Works matching IS 17762596 AND DT 2024 AND VI 19 AND IP 5

Results: 16

Efficacy and Safety of Durvalumab/Tremelimumab in Unresectable Hepatocellular Carcinoma as Immune Checkpoint Inhibitor Rechallenge Following Atezolizumab/Bevacizumab Treatment.
Published in:
Targeted Oncology, 2024, v. 19, n. 5, p. 769, doi. 10.1007/s11523-024-01092-7
By:
- Sho, Takuya;
- Suda, Goki;
- Ohara, Masatsugu;
- Kohya, Risako;
- Sasaki, Takashi;
- Yoshida, Sonoe;
- Hosoda, Shunichi;
- Ogawa, Koji;
- Kitagataya, Takashi;
- Maehara, Osamu;
- Ohnishi, Shunsuke;
- Kawagishi, Naoki;
- Natsuizaka, Mitsuteru;
- Nakai, Masato;
- Baba, Masaru;
- Yamamoto, Yoshiya;
- Tsukuda, Yoko;
- Meguro, Takashi;
- Yamada, Ren;
- Kobayashi, Tomoe
Publication type:
Article
A Phase 1a/1b Dose Escalation/Expansion Study of the Anti-PD-1 Monoclonal Antibody Nofazinlimab in Chinese Patients with Solid Tumors or Lymphoma.
Published in:
Targeted Oncology, 2024, v. 19, n. 5, p. 723, doi. 10.1007/s11523-024-01091-8
By:
- Gong, Jifang;
- Guo, Ye;
- Zhang, Yanqiao;
- Ba, Yi;
- Chen, Tong;
- Li, Wei;
- Zhou, Caicun;
- Wang, Mengzhao;
- Yang, Haiyan;
- Zhou, Yuhong;
- Cai, Qiqing;
- Wang, Ziping;
- Huang, Gang;
- Zhang, Wei;
- Su, Rila;
- Cai, Zhongheng;
- Yue, Zenglian;
- Dou, Jinzhou;
- Li, Peiqi;
- Wu, Rachel
Publication type:
Article
lnsights into Adjuvant Systemic Treatment Selection for Patients with Stage III Melanoma: Data from the Dutch Cancer Registry.
Published in:
Targeted Oncology, 2024, v. 19, n. 5, p. 735, doi. 10.1007/s11523-024-01090-9
By:
- Aldenhoven, Loeki;
- van Weezelenburg, Merel A. Spiekerman;
- van den Berkmortel, Franchette W. P. J.;
- Servaas, Nick;
- Janssen, Alfred;
- Vissers, Yvonne L. J.;
- van Haaren, Elisabeth R. M.;
- Beets, Geerard L.;
- van Bastelaar, James
Publication type:
Article
Pembrolizumab in Patients with Advanced Urothelial Carcinoma with ECOG Performance Status 2: A Real-World Study from the ARON-2 Project.
Published in:
Targeted Oncology, 2024, v. 19, n. 5, p. 747, doi. 10.1007/s11523-024-01089-2
By:
- Rizzo, Alessandro;
- Monteiro, Fernando Sabino Marques;
- Ürün, Yüksel;
- Massari, Francesco;
- Park, Se Hoon;
- Bourlon, Maria T.;
- Poprach, Alexandr;
- Rizzo, Mimma;
- Takeshita, Hideki;
- Giannatempo, Patrizia;
- Soares, Andrey;
- Roviello, Giandomenico;
- Molina-Cerrillo, Javier;
- Carrozza, Francesco;
- Abahssain, Halima;
- Messina, Carlo;
- Kopp, Ray Manneh;
- Pichler, Renate;
- Formisano, Luigi;
- Tural, Deniz
Publication type:
Article
Identifying Actionable Alterations in KRAS Wild-Type Pancreatic Cancer.
Published in:
Targeted Oncology, 2024, v. 19, n. 5, p. 679, doi. 10.1007/s11523-024-01088-3
By:
- Elhariri, Ahmed;
- Patel, Jaydeepbhai;
- Mahadevia, Himil;
- Albelal, Douaa;
- Ahmed, Ahmed K.;
- Jones, Jeremy C.;
- Borad, Mitesh J.;
- Babiker, Hani
Publication type:
Article
Patient Enrollment per Month (Accrual) in Clinical Trials Leading to the FDA Approval of New Cancer Drugs.
Published in:
Targeted Oncology, 2024, v. 19, n. 5, p. 797, doi. 10.1007/s11523-024-01081-w
By:
- Michaeli, Daniel Tobias;
- Michaeli, Thomas;
- Albers, Sebastian;
- Michaeli, Julia Caroline
Publication type:
Article
Correction to: Moving T‑Cell Therapies into the Standard of Care for Patients with Relapsed or Refractory Follicular Lymphoma: A Review.
Published in:
2024
By:
- Fowler, Nathan Hale;
- Chavez, Julio C.;
- Riedell, Peter A.
Publication type:
Correction Notice
Risk Stratification According to Baseline and Early Change in Neutrophil-to-Lymphocyte Ratio in Advanced Non-Small Cell Lung Cancer Treated with Chemoimmunotherapy: A Multicenter Real-World Study.
Published in:
Targeted Oncology, 2024, v. 19, n. 5, p. 757, doi. 10.1007/s11523-024-01084-7
By:
- Matsumoto, Kinnosuke;
- Yamamoto, Yuji;
- Shiroyama, Takayuki;
- Kuge, Tomoki;
- Mori, Masahide;
- Tamiya, Motohiro;
- Kinehara, Yuhei;
- Tamiya, Akihiro;
- Suzuki, Hidekazu;
- Tobita, Satoshi;
- Ueno, Kiyonobu;
- Niki, Toshie;
- Nagatomo, Izumi;
- Takeda, Yoshito;
- Kumanogoh, Atsushi
Publication type:
Article
Author's Reply to Ma et al.: "Hematological Toxicity of PARP Inhibitors in Metastatic Prostate Cancer Patients with Mutations of BRCA or HRR Genes: A Systematic Review and Safety Meta-analysis".
Published in:
2024
By:
- Maiorano, Brigida Anna;
- Necchi, Andrea;
- Di Maio, Massimo
Publication type:
Letter
Comment on: "Hematological Toxicity of PARP Inhibitors in Metastatic Prostate Cancer Patients with Mutations of BRCA or HRR Genes: A Systematic Review and Safety Meta‑analysis".
Published in:
2024
By:
- Ma, Jun;
- Han, Wei
Publication type:
Letter
An Evidence-Based Rationale for Dose De-escalation of Subcutaneous Atezolizumab.
Published in:
Targeted Oncology, 2024, v. 19, n. 5, p. 779, doi. 10.1007/s11523-024-01087-4
By:
- Kicken, Mart P.;
- Deenen, Maarten J.;
- Moes, Dirk J. A. R.;
- Hendrikx, Jeroen J. M. A.;
- van den Borne, Ben E. E. M.;
- Dumoulin, Daphne W.;
- van der Wekken, Anthonie J.;
- van den Heuvel, Michiel M.;
- ter Heine, Rob
Publication type:
Article
Current State of Targeted Therapy in Adult Langerhans Cell Histiocytosis and Erdheim–Chester Disease.
Published in:
Targeted Oncology, 2024, v. 19, n. 5, p. 691, doi. 10.1007/s11523-024-01080-x
By:
- Lin, He;
- Cao, Xin-xin
Publication type:
Article
Malignant Peripheral Nerve Sheath Tumor, a Heterogeneous, Aggressive Cancer with Diverse Biomarkers and No Targeted Standard of Care: Review of the Literature and Ongoing Investigational Agents.
Published in:
Targeted Oncology, 2024, v. 19, n. 5, p. 665, doi. 10.1007/s11523-024-01078-5
By:
- Somaiah, Neeta;
- Paudyal, Bishnuhari;
- Winkler, Robert E.;
- Van Tine, Brian A.;
- Hirbe, Angela C.
Publication type:
Article
Safety and Preliminary Efficacy of Once-Weekly Split-Dose Selinexor in Soft Tissue Sarcoma: Results of the Phase Ib METSSAR Clinical Trial.
Published in:
Targeted Oncology, 2024, v. 19, n. 5, p. 711, doi. 10.1007/s11523-024-01076-7
By:
- Salawu, Abdulazeez;
- Malone, Eoghan R.;
- Al-Ezzi, Esmail;
- Genta, Sofia;
- Vornicova, Olga;
- Wang, Lisa;
- Arones, Limore;
- Phillips, Madeline;
- Lee, Jasmine;
- Watson, Geoffrey A.;
- Gupta, Abha A.;
- Abdul Razak, Albiruni R.
Publication type:
Article
Model-Informed Development of a Cost-Saving Dosing Regimen for Sacituzumab Govitecan.
Published in:
Targeted Oncology, 2024, v. 19, n. 5, p. 789, doi. 10.1007/s11523-024-01075-8
By:
- Moes, Dirk J. A. R.;
- Hendrikx, Jeroen J. M. A.;
- Guchelaar, Henk-Jan;
- Mathijssen, Ron H. J.;
- Bakker, J. L.;
- Dezentjé, Vincent O.;
- de Rouw, Nikki;
- van Erp, Nielka P.;
- Smit, Egbert F.;
- van den Heuvel, Michel M.;
- Munnink, Thijs H. Oude;
- van Kats, Maartje;
- Croes, Sander;
- Kroep, Judith R.;
- Zwaveling, Juliette;
- ter Heine, Rob
Publication type:
Article
Trastuzumab-Deruxtecan: Redefining HER2 as a Tumor Agnostic Biomarker.
Published in:
Targeted Oncology, 2024, v. 19, n. 5, p. 705, doi. 10.1007/s11523-024-01079-4
By:
- Zouein, Joseph;
- Karam, Elias;
- Strickler, John H.;
- Kourie, Hampig Raphael
Publication type:
Article